Insider Selling: TESARO Inc (TSRO) SVP Sells 371 Shares of Stock
TESARO Inc (NASDAQ:TSRO) SVP Martin H. Jr. Huber sold 371 shares of the firm’s stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $37.63, for a total transaction of $13,960.73. Following the completion of the transaction, the senior vice president now directly owns 12,577 shares of the company’s stock, valued at approximately $473,272.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of TESARO stock opened at $37.31 on Wednesday. TESARO Inc has a 52-week low of $25.62 and a 52-week high of $129.64. The company has a quick ratio of 3.64, a current ratio of 4.11 and a debt-to-equity ratio of -29.71. The company has a market capitalization of $2.07 billion, a P/E ratio of -4.07 and a beta of 1.08.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($3.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.66) by ($0.38). TESARO had a negative return on equity of 285.30% and a negative net margin of 180.29%. The firm had revenue of $57.21 million during the quarter, compared to analysts’ expectations of $65.50 million. During the same quarter in the prior year, the firm earned ($2.82) EPS. The firm’s revenue was up 94.2% compared to the same quarter last year. equities research analysts anticipate that TESARO Inc will post -11.09 EPS for the current fiscal year.
Several research analysts have recently commented on TSRO shares. Barclays lowered their price objective on shares of TESARO from $60.00 to $56.00 and set an “overweight” rating for the company in a research note on Monday, August 6th. Bank of America lowered shares of TESARO from a “buy” rating to a “neutral” rating in a research note on Monday, August 6th. Cann reissued a “buy” rating and issued a $83.00 price objective on shares of TESARO in a research note on Tuesday, September 4th. Citigroup lowered their price objective on shares of TESARO from $100.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, August 29th. Finally, Zacks Investment Research lowered shares of TESARO from a “hold” rating to a “sell” rating in a research note on Tuesday, July 3rd. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $79.61.
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Read More: Market Capitalization
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.